• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

BMS signs $674M biobucks pact with Roivant's VantAI for molecular glues

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 13, 2024 at 12:12: PM
via Bristol Myers Squibb is offering Roivant's VantAI up to $674 million biobucks in a new partnership aimed at designing molecular glues as small-molecule therapeutics.

article source
 

<



Similar threads

cafead
BMS signs ADC development deal with Munich-based biotech worth more than $1B
Replies
0
Views
209
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BMS joins Octant’s $80M financing and signs on as a drug discovery partner
Replies
0
Views
126
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA weighs limiting PD-1 drugs in stomach cancer, calls on experts to discuss Merck, BMS and BeiGene meds
Replies
0
Views
32
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer
Replies
0
Views
9
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
Replies
0
Views
44
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote